CA3230307A1 - Thiadiazolone derivatives useful as ampk activator - Google Patents
Thiadiazolone derivatives useful as ampk activator Download PDFInfo
- Publication number
- CA3230307A1 CA3230307A1 CA3230307A CA3230307A CA3230307A1 CA 3230307 A1 CA3230307 A1 CA 3230307A1 CA 3230307 A CA3230307 A CA 3230307A CA 3230307 A CA3230307 A CA 3230307A CA 3230307 A1 CA3230307 A1 CA 3230307A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- oxo
- hydrogen
- methyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2112529.9A GB202112529D0 (en) | 2021-09-02 | 2021-09-02 | New compounds |
| GB2112529.9 | 2021-09-02 | ||
| PCT/GB2022/052234 WO2023031609A1 (en) | 2021-09-02 | 2022-09-01 | Thiadiazolone derivatives useful as ampk activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3230307A1 true CA3230307A1 (en) | 2023-03-09 |
Family
ID=78076730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3230307A Pending CA3230307A1 (en) | 2021-09-02 | 2022-09-01 | Thiadiazolone derivatives useful as ampk activator |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250136563A1 (enExample) |
| EP (1) | EP4396171A1 (enExample) |
| JP (1) | JP2024535745A (enExample) |
| KR (1) | KR20240055039A (enExample) |
| CN (1) | CN118510762A (enExample) |
| AU (1) | AU2022336441A1 (enExample) |
| CA (1) | CA3230307A1 (enExample) |
| GB (1) | GB202112529D0 (enExample) |
| IL (1) | IL310871A (enExample) |
| MX (1) | MX2024002674A (enExample) |
| WO (1) | WO2023031609A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3075388T3 (en) | 2019-10-18 | 2026-08-04 | Betagenon Ab | New formulations |
| GB202015585D0 (en) | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
| WO2025252672A1 (en) * | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200720264A (en) * | 2005-04-25 | 2007-06-01 | Lundbeck & Co As H | Pro-drugs of n-thiazol-2-yl-benzamide derivatives |
| US20090156644A1 (en) * | 2005-07-21 | 2009-06-18 | Jacob Westman | Use of thiazole derivatives and analogues in the treatment of cancer |
| AU2010270030B2 (en) * | 2009-07-08 | 2015-12-24 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| JP2013230986A (ja) * | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | 新規ヒダントイン誘導体及びそれらを有効成分とする医薬 |
| KR101889993B1 (ko) * | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| CN111848579B (zh) * | 2019-04-26 | 2023-11-14 | 君实润佳(上海)医药科技有限公司 | 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药 |
| GB202015585D0 (en) * | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
-
2021
- 2021-09-02 GB GBGB2112529.9A patent/GB202112529D0/en not_active Ceased
-
2022
- 2022-09-01 US US18/684,154 patent/US20250136563A1/en active Pending
- 2022-09-01 AU AU2022336441A patent/AU2022336441A1/en active Pending
- 2022-09-01 MX MX2024002674A patent/MX2024002674A/es unknown
- 2022-09-01 WO PCT/GB2022/052234 patent/WO2023031609A1/en not_active Ceased
- 2022-09-01 CN CN202280073480.7A patent/CN118510762A/zh active Pending
- 2022-09-01 JP JP2024514006A patent/JP2024535745A/ja active Pending
- 2022-09-01 CA CA3230307A patent/CA3230307A1/en active Pending
- 2022-09-01 KR KR1020247010453A patent/KR20240055039A/ko active Pending
- 2022-09-01 EP EP22792860.3A patent/EP4396171A1/en active Pending
- 2022-09-01 IL IL310871A patent/IL310871A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250136563A1 (en) | 2025-05-01 |
| IL310871A (en) | 2024-04-01 |
| EP4396171A1 (en) | 2024-07-10 |
| AU2022336441A1 (en) | 2024-03-07 |
| WO2023031609A1 (en) | 2023-03-09 |
| CN118510762A (zh) | 2024-08-16 |
| JP2024535745A (ja) | 2024-10-02 |
| MX2024002674A (es) | 2024-03-19 |
| KR20240055039A (ko) | 2024-04-26 |
| GB202112529D0 (en) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7372957B2 (ja) | アミノピリミジンｓｓａｏ阻害剤 | |
| AU784007B2 (en) | Inhibitors of dipeptidyl peptidase IV | |
| US20250136563A1 (en) | Thiadiazolone derivatives useful as ampk activator | |
| KR100967070B1 (ko) | 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제 | |
| EP4222147B1 (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| JP2013527124A (ja) | オピオイドの新規カルバマートアミノ酸およびペプチドプロドラッグならびにその使用 | |
| AU2002302857A1 (en) | 3-fluoro-pyrrolidines as antidiabetic agents | |
| EP1757582A1 (en) | Arylalkylamines and process for production thereof | |
| JP2004534815A (ja) | 抗糖尿病薬としての３−フルオロ−ピロリジン | |
| WO2007142253A1 (ja) | ２－シアノピロリジン誘導体 | |
| JP7854780B2 (ja) | 核内受容体に対して活性の化合物 | |
| WO2020006177A1 (en) | Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof | |
| US20230141981A1 (en) | Novel compounds and composition for targeted therapy of kidney-associated cancers | |
| KR20000035930A (ko) | 티아졸릴-알라닌 잔기를 갖는 신규한 펩티드 유도체 | |
| US20070088021A1 (en) | 4-haloisoquinoline derivative and drug containing the same | |
| US20130310396A1 (en) | Thiazolidine derivatives and their therapeutic use | |
| PT100700A (pt) | Composicao farmaceutica a base de compostos inibidores da renina | |
| US5523289A (en) | Pharmaceutical composition | |
| US20200246317A1 (en) | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent | |
| HK40092998B (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| HK40092998A (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| JP2021513564A (ja) | グルカゴン受容体拮抗薬 | |
| DE69326555T2 (de) | Ethynyl-alanin-aminodiolverbindungen mit piperazinylendgruppe oder piperazinyl-alkylamino-endgruppe zur behandlung von bluthochdruck | |
| JP4842254B2 (ja) | Ｐａｒ−２アゴニスト | |
| JP2009137864A (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |